MACK Share Price

Open 14.96 Change Price %
High 15.09 1 Day -0.64 -4.30
Low 13.98 1 Week -0.31 -2.13
Close 14.26 1 Month 12.94 980.30
Volume 190933 1 Year 8.28 138.46
52 Week High 15.40
52 Week Low 1.13
MACK Important Levels
Resistance 2 15.29
Resistance 1 14.86
Pivot 14.44
Support 1 13.66
Support 2 13.23
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK)

MACK Technical Analysis 5
As on 22nd Sep 2017 MACK Share Price closed @ 14.26 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.75 & Strong Buy for SHORT-TERM with Stoploss of 4.30 we also expect STOCK to react on Following IMPORTANT LEVELS.
MACK Target for September
1st Target up-side 1.48
2nd Target up-side 1.56
3rd Target up-side 1.65
1st Target down-side 1.24
2nd Target down-side 1.16
3rd Target down-side 1.07
MACK Other Details
Segment EQ
Market Capital 657907328.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.merrimackpharma.com
MACK Address
MACK
One Kendall Square
Suite B7201
Cambridge, MA 02139
United States
Phone: 617-441-1000
Fax: 617-491-1386
MACK Latest News
Interactive Technical Analysis Chart Merrimack Pharmaceuticals, Inc. ( MACK NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Merrimack Pharmaceuticals, Inc.
MACK Business Profile
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�s product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. The Company�s Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.